Dawn of CAR-T cell therapy in autoimmune diseasesOACSTPCDMEDLINE
Dawn of CAR-T cell therapy in autoimmune diseases
Chimeric antigen receptor(CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies.Based on the immunomodulatory capability of CAR-T cells,efforts have turned toward exploring their potential in treating auto-immune diseases.Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases,covering a range of subtypes such as systemic lupus erythematosus,multiple sclerosis,among others.CAR-T therapy holds promise in mitigating several shortcomings,including the indiscriminate suppression of the immune system by traditional immunosuppressants,and non-sus-taining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints.By persisting and proliferating in vivo,CAR-T cells can offer a tailored and precise therapeutics.This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases,incorporating innovations well-studied in the field of hematological tumors,aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.
Yuxin Liu;Lifang Zhu;Jun Xiao;Wei Wang;Chuan Qin;Daishi Tian;Minghao Dong;Yunhui Chu;Luoqi Zhou;Yunfan You;Xiaowei Pang;Sheng Yang;Luyang Zhang;Lian Chen
Department of Neurology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China||Hubei Key Laboratory of Neural Injury and Functional Reconstruction,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China
CAR-T cell therapyAutoimmune diseaseImmunotherapyMultiple sclerosisNeuromyelitis optica spectrum disorderSystemic lupus erythematosus
《中华医学杂志（英文版）》 2024 (010)
1140-1150 / 11
This study was supported by grants from the Ministry of Science and Technology China Brain Initiative Grant STI2030-Major Projects(No.2022ZD0204700),the National Natural Science Foundation of China(Nos.82371404,82271341,82071380,and 81873743),and the Knowledge Innovation Program of Wuhan Shuguang Project(No.2022020801020454).
评论